Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder in which preferential loss of motor neurons (MNs) results in paralysis and death. Although ALS is largely a sporadic disease, research has focused on heritable forms of the disorder because clinical and pathological evidence suggests common pathogenic mechanisms. Mutations in the gene FUS cause some of the most aggressive early-onset forms of ALS. FUS pathology ? and rarely, mutations - are also associated with the related neurodegenerative disorder, frontotemporal dementia (FTD). In a recent study, our lab demonstrated in a mouse model of disease that mutant FUS causes motor neuron degeneration not by a loss-of-function, by a toxic gain-of-function that does not involve an excess of FUS activity. FUS is one of a number of RNA binding proteins ? including TDP-43 and hnRNP A1 ? that have been causally related to ALS and FTD. Recent work has led to a disease model in which the intrinsically disordered ?prion-like? domain of FUS and related proteins drives a phase transition that results in the formation of an irreversible, neurotoxic aggregate. ALS-related mutations in FUS increase the natural tendency of the protein to form these toxic assemblies, which trap and sequester other ribonucleoprotein granule components. In this project we will explore the mechanisms of FUS toxicity in a novel series of knock-in mutant mice that reproduce key aspect of the FUS-ALS phenotype. In addition, in vitro studies using motor neurons and astrocytes derived from these mouse models will be used to investigate cell autonomous and non- autonomous mechanisms of disease.
In Aim 1, we will use a conditional knock-in mouse model to express mutant FUS in MNs or astrocytes, or more broadly in the nervous system to explore the effects of temporally and spatially regulated mutant FUS expression on MN survival and function; and we will also explore the relative toxicity of human FUS in a fully humanized mouse model of FUS-ALS. In this highly disease-relevant model of ALS/FTD, we will also test the therapeutic potential of the FUS disaggregase, Kap?2 as a means to slow or stop the onset and progression of MN degeneration.
In Aim 2, we will combine sophisticated electrophysiological and behavioral methods to explore the functional consequence of mutant FUS throughout disease progression in the FUS knock-in mouse. Finally in Aim 3, we will apply a combination of single-cell RNA sequencing and topological data analysis to a mixed distribution of in vitro differentiated MNs derived from our FUS knock-in mutant mice. This sophisticated integration of in vivo and in vitro experimental systems, combined with our integrative computational and analytical approach will allow us to elucidate pathways of disease in vulnerable subpopulations of MNs and to identify potential therapeutic targets for the treatment of FUS-ALS and related forms of motor neuron disease.
Amyotrophic lateral sclerosis (ALS or Lou Gehrig?s Disease) is a fatal disease of motor neurons. Mutations in the gene FUS cause familial and sporadic forms ALS, and FUS pathology is also found in the related neurodegenerative disorder, frontotemporal dementia (FTD). In novel animal and cellular models of ALS, this project will elucidate toxic gain-of-function mechanisms by which mutant FUS causes motor neuron and frontotemporal degeneration. This effort will test one promising approach to the treatment of FUS-ALS and FTD, and provide important insights that will lead to the development of other novel therapies.
